R-Pharm Overseas, Inc.
🇺🇸United States
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- R-Pharm Overseas, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05107934
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
Phase 2
Completed
- Conditions
- Acute ST Segment Elevation Myocardial Infarction
- Interventions
- Biological: RPH-104 80 mgDrug: Placebo
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- R-Pharm Overseas, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT04463251
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸VCU Health-Virginia Commonwealth University Health, Richmond, Virginia, United States
Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
Phase 2
Withdrawn
- Conditions
- Schnitzler SyndromeUrticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- R-Pharm Overseas, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04213274
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
News
No news found